Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 243-929-9 | CAS number: 20634-12-2
Endpoint summary
Administrative data
Description of key information
In an OECD Test Guideline 421 reproductive/developmental toxicity screening study, to GLP, in rats with tetraammineplatinum dinitrate, the general systemic toxicity NOAEL for females was 250 mg/kg bw/day on the basis of reduced growth at the highest tested dose (1000 mg/kg bw/day). No adverse effects were observed in males at any dose (Hansen, 2015).
No repeated dose toxicity studies by the inhalation or dermal route were identified, or are required.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 250 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Overall, good-quality database which meets REACH Standard Information Requirements.
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Mode of Action Analysis / Human Relevance Framework
No data identified.
Additional information
No relevant human data were identified.
No specific repeated dose toxicity studies were identified for tetraammineplatinum dinitrate, or are required at this tonnage (1-10 tpa).
In an OECD Test Guideline 421 reproductive/developmental toxicity study, conducted according to GLP, rats (12/sex/group) received a solution of tetraammineplatinum dinitrate by gavage at doses of 0, 50, 250 or 1000 mg/kg bw/day for at least 28 days (males were dosed for 28 days in total, while females received treatment for a longer period of time [incorporating the gestation period and proceeding up until post-partum day 3, test day 40-47]). This reproductive and developmental screening assay has some limitations compared to a standard repeated dose assay for assessing general systemic toxicity (e.g. no haematology, clinical chemistry or urinalysis; histopathology was limited to the high dose group). The only clinical sign of toxicity was a significantly reduced body weight in high-dose females at the end of the study on post-partum day 4. No adverse effects were observed in males at any dose. There was no impact on food consumption in males or females. Thus, the NOAEL for general toxicity was deemed to be 250 mg/kg bw/day (Hansen, 2015).
Justification for classification or non-classification
No adverse systemic effects were seen in the reliable guideline reproductive/developmental screening assay on tetraammineplatinum dinitrate. The reduced growth seen at the highest tested dose (1000 mg/kg bw/day) in females alone is not considered sufficient for classification as STOT-RE. As such, the results of this study indicate that classification as STOT-RE is not required, according to EU CLP criteria (EC 1272/2008).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
